Published in final edited form as:
Cancer Immunol Immunother. 2009 April ; 58(4): 475–492. doi:10.1007/s00262-008-0598-y.

Combination of Active Specific Immunotherapy or Adoptive Antibody or Lymphocyte Immunotherapy with Chemotherapy in the Treatment of Cancer

Tianqian Zhang and **Dorothee Herlyn**[1]
[1]The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104

Abstract

Successful treatment of cancer patients with a combination of monoclonal antibodies (mAb) and chemotherapeutic drugs has spawned various other forms of additional combination therapies, including vaccines or adoptive lymphocyte transfer combined with chemotherapeutics. These therapies were effective against established tumors in animal models and showed promising results in initial clinical trials in cancer patients, awaiting testing in larger randomized controlled studies. Although combination between immunotherapy and chemotherapy has long been viewed as incompatible as chemotherapy, especially in high doses meant to increase anti-tumor efficacy, has induced immunosuppression, various mechanisms may explain the reported synergistic effects of the two types of therapies. Thus direct effects of chemotherapy on tumor or host environment, such as induction of tumor cell death, elimination of regulatory T cells, and/or enhancement of tumor cell sensitivity to lysis by CTL may account for enhancement of immunotherapy by chemotherapy. Furthermore, induction of lymphopenia by chemotherapy has increased the efficacy of adoptive lymphocyte transfer in cancer patients. On the other hand, immunotherapy may directly modulate the tumor's sensitivity to chemotherapy. Thus, anti-tumor mAb can increase the sensitivity of tumor cells to chemotherapeutic drugs and patients treated first with immunotherapy followed by chemotherapy showed higher clinical response rates than patients that had received chemotherapy alone. In conclusion, combination of active specific immunotherapy or adoptive mAb or lymphocyte immunotherapy with chemotherapy has great potential for the treatment of cancer patients which needs to be confirmed in larger controlled and randomized Phase III trials.

Keywords

Cancer; Immunotherapy; Chemotherapy; Antibody; Vaccine; Lymphocyte

Introduction

Combination between immunotherapy and chemotherapy has long been viewed as incompatible as chemotherapy, especially at high doses meant to increase the anti-tumor efficacy, has induced immunosuppression. Possible mechanisms of immune suppression by chemotherapy are induction of lymphopenia, immunosuppressive cytokines, immune tolerance by high doses of antigens released by the dying tumor cells, and inhibition of immune effector cell function [3,90,94,155]. However, in the 1960s, Mihich already demonstrated in murine leukemia model that the curative effects of chemotherapy are due to the induction of immune response directed against the tumor cells [91-93]. Immunoaugmentation has also been shown

e-mail: dherlyn@wistar.org.

in later studies following chemotherapy with some drugs at low doses [3,47,90,94,155]. Treatment of cytotoxic T lymphocytes (CTL) with certain chemotherapeutic drugs enhanced their capacity to lyse Epstein Barr virus (EBV)-transformed lymphocytes, whereas other drugs showed inhibitory activities [86]. Experimental evidence has shown that direct effects of chemotherapy on tumor and host environment, which are discussed in detail below, may counteract its immunosuppressive effects, leading to enhancement of anti-tumor immune response. We have reviewed here experimental and clinical approaches to combining active specific immunotherapy, or adoptive antibody or cellular immunotherapy with chemotherapy in the treatment of cancer. Most of the previous review articles did not cover combination of adoptive antibody or cellular immunotherapy with chemotherapy in pre-clinical and clinical studies and, in contrast to our article, none (including also articles on combined active specific immunotherapy and chemotherapy) describe experimental details, which are important to better understand differences in the results obtained with similar combination therapies by different investigators [3,18,21,32,45,48,58,73-75,77,83,90,95,96,101,117,123,132,137,143, 144]. The experimental approaches in this review include only studies which are carefully controlled to demonstrate that a combination of both therapies is superior to the use of either therapy alone. Clinical trials with combination therapies are also included in this review although they were not randomized controlled and have not yet reached phase III. This review article does not include studies in which non-specific immune modulators such as cytokines were combined with chemotherapeutic agents. These studies have recently been reviewed by Zitvogel et al. [155].

Pre-clinical and clinical studies of combined mAb IT and CT

MAb therapy, which has long been viewed as unsuccessful, has been greatly rejuvenated by its combination with chemotherapeutics. Naked and radiolabelled mAb in combination with chemotherapeutics, or mAb linked to drugs have been used for the treatment of various malignancies in mice and cancer patients (Tables 1 and 2). In mice, the anti-tumor effects of these combination therapies were significantly greater compared to either therapy alone. Of note, in each of the experimental studies (Table1), significant effects were seen against established tumors. In cancer patients, impressive clinical responses were reported with combination therapies targeting specifically CD33 in leukemias, CD20 in B cell lymphomas, HER-2 in breast carcinomas, and epidermal growth factor receptor (EGF-R) in head and neck carcinomas (Table 2). The possible mechanisms underlying therapeutic effects of this combination therapy are discussed below.

Pre-clinical and clinical studies of combined active specific IT and CT

The possible mechanisms underlying synergistic effects of active specific IT and CT are quite well understood, but selection of optimal dose of chemotherapy and timing of administration of the two therapies remain a challenge (see below). Various forms of vaccine delivery, such as irradiated tumor cells, tumor cell extract, tumor proteins or antigens expressed in naked plasmids or viral vectors have been used in combination with chemotherapeutics in several tumor models in mice (Table 3). In some of these studies, combination therapy was able to inhibit growth of established tumors [2,19,28,46,49,61,65,67,69,70,72,76,109,130,140,141, 153,154]. In clinical trials in which combined vaccine/chemotherapy was compared with either therapy or IT alone, promising clinical responses have been reported. Thus, the number of glioblastoma patients demonstrating 2yr disease-free survival was increased after treatment with dendritic cells (DC) loaded with tumor peptides or lysates, followed by chemotherapy with Temozolomide and BCNU as compared to treatment with either therapy alone [148] (Table 4). Clinical response rates of prostate cancer patients were increased following immunization with tumor peptides in combination with chemotherapy (Estramustine phosphate) as compared to IT alone [103] (Table 4). In another trial in prostate cancer patients,

median time to tumor progression was increased after combination therapy (recombinant vaccinia virus expressing prostate specific antigen, followed by doxorubicin), compared to IT alone [6] (Table 4).

Pre-clinical and clinical studies of adoptive lymphocyte or active specific IT in combination with lymphodepletion by CT

The combination of adoptive lymphocyte IT with lymphodepletion by CT in patients with refractory metastatic (stage IV) melanoma has resulted in remarkable clinical response rates of approximately 50% [44] (Table 5), whereas clinical response rates with various CTs or adoptive lymphocyte transfer alone usually ranged between 10% and 34% in historical control patients [128,129]. Various mechanisms may underly the synergistic effects of lymphodepletion on adoptive lymphocyte IT (see below). Lymphodepletion also has been combined with both active specific and adoptive lymphocyte IT in 6 metastatic melanoma patients. Thus, each patient received all three therapies [5] (Table 5). Only 1 of 6 patients showed a partial response to this combination therapy and it is unclear which form of therapy this response may be attributed to.

Treatment of well established tumors in mice with a chemotherapeutic drug, followed by adoptive lymphocyte IT resulted in tumor regression [152] (Table 5). Interestingly, synergism between the two therapies was dependent on the tumor microenvironment (see below).

Discussion and conclusions

The major possible direct effects of chemotherapy on tumor and/or host environment, which provide a rationale for combining CT with active and/or adoptive cellular IT, are:

a. Induction of tumor cell death

In the early studies by Bonmassar, it was shown that various types of immunogenic modification of tumor cells might occur in tumor-bearing hosts after treatment with drugs in vivo [15,52,68,102,125]. The molecular mechanism of drug-mediated immunogenic changes could be related to somatic mutations [51,56]. Notably, chemotherapy of tumor-bearing mice and breast cancer patients was followed by induction of immune responses to the tumors [66, 97,104,109,125]. Induction of necrosis and/or apoptosis in tumor cells in vitro has frequently been shown to increase their immunogenicity in vivo [3,20,54,78,90,94,107,124]. Most likely, necrotic or apoptotic tumor cells induced by chemotherapy were phagocytosed by antigen-presenting cells (APC), presented to immune lymphocytes, followed by the stimulation of an anti-tumor responses in the lymphocytes [3,55,79,90,94]. Through induction of cell death by chemotherapeutics, a tumor could become its own cellular vaccine by crosspresentation of the apoptotic cells to APC, or induction of pro-inflammatory mediators such as heat shock proteins or interleukin (IL)-6, followed by crosspriming of immune effector cells [80,145]. Although different chemotherapeutic agents may kill tumor cells through an apparently homogeneous apoptotic pathway, they may differ in the mechanism underlying the induction of immunogenic cell death. Thus, the chemotherapeutic agent anthracyclin induced an immune response to tumor cells only when apoptosis was preceded by translocation of calreticulin to the plasma membrane. Blockade or knock-down of calreticulin suppressed the phagocytosis of anthracyclin-treated tumor cells by dendritic cells and abolished their immunogenicity in mice [3,90,106,107].

In principle, any therapy that delivers higher levels of cross-presented tumor antigens to the draining lymph nodes could synergize with immunotherapy. Thus, anti-tumor immunity induced by apoptotic tumor cells following chemotherapy can be boosted by active specific immunotherapy (see Tables 3 and 4).

b. Elimination of regulatory T (Treg) cells

Cyclophosphamide (Cy) may down regulate the activity of Treg, especially when used in low doses [3,82,84,90,94,99], whereas high doses may have direct tumor-cytotoxic effects [97-99]. Cy has been widely used in conjunction with active specific IT to enhance anti-tumor immune responses by down regulation of Treg, and this combination therapy has been pioneered by Berd et al. ([12,13]; Table 3).

c. Enhancement of tumor cell sensitivity to lysis by CTL

Active specific immunotherapy often induces low avidity CTL which do not effectively lyse tumors. However, when melanoma cells were treated with chemotherapeutic agents in vitro, they became highly sensitive to lysis by low avidity CTL. Cytotoxic drug-mediated sensitization primed both perforin/granzyme and Fas-mediated killing by the CTL [151]. In a related study, treatment of cancer cells with 5-aza-2'-deoxycytidine restored the expression of major histocompatibility complex (MHC) class I molecules and cancer testis antigens on tumor cells, rendering the tumor cells susceptible to CTL attack [133].

In a reverse manner, immunotherapy may directly modulate the tumor's sensitivity to chemotherapy:

a. Monoclonal antibody Rituximab, used for passive immunotherapy of B cell lymphoma and non-Hodgkin's lymphoma cancer patients, has reverted chemoresistance in B cell lymphoma cell lines to chemosensitivity [33]. Chemosensitization of tumor cells was due to downregulation of TNF-alpha secretion, but not to downmodulation of either the MDR-1 or bcl-2 gene products. Also, Her2-neu downregulation by mAb Herceptin increased tumor cell sensitivity to cisplatin by decreasing DNA repair activity following cisplatin-induced DNA damage [62,115].

b. In several clinical trials, IT was followed by salvage CT [4,6,103,148] (Table 4). Patients treated with this combination therapy showed higher clinical response rates as compared to historical controls treated with CT alone, although larger randomized and carefully controlled trials must be conducted to convincingly demonstrate beneficial effects of combination therapies. It is not known whether in the trials mentioned above IT “conditioned” the tumor to destruction by CT as shown for combinations of mAb and CT [33,62,115]. Gabrilovich [53] suggests that the anti-tumor effects of IT followed by CT are exerted independently by the two therapies and synergistic effects of this combination therapy may be dependent on optimal timing and scheduling of the two therapies. Specifically, CT may need to be started quickly after the administration of IT as anti-tumor immune responses generated by IT can not be sustained for a long period of time in cancer patients [53]. On the other hand, studies in tumor-bearing experimental animals have shown that delaying CT after IT increases the anti-tumor efficacy of this combined treatment, evidently through inhibition of vaccine-induced regulatory T cells by the chemotherapeutic drug [28] (Table 3).

The therapeutic induction of lymphopenia has raised considerable interest in the context of adoptive lymphocyte transfer therapies and vaccination of melanoma patients [100]. Transient lymphopenia is thought to enhance the efficiency of these therapies by activating homeostatic mechanisms that stimulate the tumor-reactive effector T cells and by counteracting tumor-induced suppression by mechanisms such as regulatory T cells or other mechanisms. Lymphodepletion also enhances T cell homing into tumor beds and intra-tumoral proliferation of effector cells [42,44] (Table 5).

In an animal model, synergism between CT and adoptive lymphocyte IT was dependent on the involvement of the tumor microenvironment [152] (Table 5). Thus, treating well established tumors expressing low levels of antigen with a chemotherapeutic drug caused sufficient release

of antigen to sensitize stromal cells for destruction by adoptively transferred cytotoxic T cells (CTL), resulting in tumor growth inhibition.

In summary, the demonstration of statistically significant survival enhancement in cancer patients treated in randomized phase III trials with mAb and CT vs patients treated with either therapy alone, raises great expectations for combination therapies consisting of active specific IT or adoptive lymphocyte IT with CT, as suggested by studies in experimental animals.

Acknowledgments

We thank Marion Sacks for editorial assistance. This work was supported by grants CA25874, CA93372, CA89480 and CA10815 from the National Institutes of Health.

Abbreviations

5-FC, 5-fluorocytosine
5-FU, 5-fluorouracil
Ab, Antibody
Ad, Adenovirus
Ag, Antigen
ADCC, Antibody-dependent cell-mediated cytotoxicity
AML, Acute myelogenous leukemia
APC, Antigen-presenting cells
BCG, Bacillus Calmette Guerin
BCNU, 1, 3-bis-(2-chloroethyl)-1-nitrosourea
CDC, Complement-dependent cytotoxicity
CDDP, Cisplatin
CEA, Carcinoembryonic antigen
CFA, Complete Freund's adjuvant
cFGFR, Chicken fibroblast growth factor receptor
CH-DOX, Chitosan hydrogel containing doxorubicin
CPA, Cyclophosphamide
CPT, 11, irinotecan
CR, Complete response
CRp, Remission with incomplete platelet recovery
CT, Chemotherapy
CTL, Cytotoxic T lymphocytes
CY, Cydophosphamide
DC, Dendritic cells
DFS, Disease-free survival
DOX, Doxorubicin
EBV, Epstein Barr virus
EGF-R, Epidermal growth factor receptor
EGP40, Epithelial glycoprotein 40
GITR, Glucocorticoid-induced TNFR family-related receptor
HPV, Human papilloma virus
i.d., Intradermally
IFA, Incomplete Freund's adjuvant
IL, Interleukin
i.m., Intramuscularly
i.p., Intraperitoneally
IT, Immunotherapy
i.v., Intravenously

LAMP, Lysosome-associated membrane protein
mAb, Monoclonal antibody
MCL, Mantle cell lymphoma
MHC, Major histocompatibility complex
MR, Mixed response
MTX, Methotrexate
MVA, Modified vaccinia Ankara
NA, No assessment
NR, no response
NT, Not tested
OR, Objective (>50%) regression
PD, Progressive disease
pfu, Plaque forming units
PKA, Protein kinase
PMT, Progression median time
p.o., Per os
PR, Partial response
PSA, Prostate-specific antigen
rF, Recombinant fowlpox virus
rV, Recombinant vaccinia virus
s.c., Subcutaneously
SD, Stable disease
SINCP, Sindbis virus
TAP, Tumor associated peptides
TAX, Paclitaxel
TGF, Transforming growth factor
TIL, Tumor infiltrating lymphocytes
TMTX, Antifolate trimetrexate
Treg, Regulatory T cells
TS-1, 5-FU derivative
VBL, Vinca alkaloid vinblastine
VEGFR, Vascular endothelial growth factor receptor
VP-16, Topoisomerase II inhibitor etoposide
VRP, Venezuelan equine encephalitis virus replicon particles

References

1. Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res 1999;59:4761–4. [PubMed: 10519379]
2. Akbulut H, Tang Y, Akbulut KG, Maynard J, Zhang L, Deisseroth A. Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer. Mol Cancer Ther 2006;5:1975–85. [PubMed: 16928818]
3. Andersen MH, Sorensen RB, Schrama D, Svane IM, Becker JC, Thor Straten P. Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother 2008;57:1735–43. [PubMed: 18286284]
4. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee JH, Menander K, Chada S, Gabrilovich DI. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878–87. [PubMed: 16467102]
5. Appay V, Voelter V, Rufer N, Reynard S, Jandus C, Gasparini D, Lienard D, Speiser DE, Schneider P, Cerottini JC, Romero P, Leyvraz S. Combination of transient lymphodepletion with busulfan and

fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J Immunother 2007;30:240–50. [PubMed: 17471171]

6. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J, Dahut W. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12:1260–9. [PubMed: 16489082]
7. Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P, Allal C. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol 2006;57:709–18. [PubMed: 16320055]
8. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825–31. [PubMed: 9661897]
9. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr. Mendelsohn J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327–33. [PubMed: 8340945]
10. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904–14. [PubMed: 10673534]
11. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, Eckardt A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568–77. [PubMed: 16009950]
12. Berd D. Low doses of chemotherapy to inhibit suppressor T cells. Prog Clin Biol Res 1989;288:449–58. [PubMed: 2566177]
13. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res 1988;48:1671–5. [PubMed: 2830969]
14. Bianchi G, Albanell J, Eiermann W, Vitali G, Borquez D, Vigano L, Molina R, Raab G, Locatelli A, Vanhauwere B, Gianni L, Baselga J. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 2003;9:5944–51. [PubMed: 14676119]
15. Bonmassar E, Testorelli C, Franco P, Goldin A, Cudkowicz G. Changes of the immunogenic properties of a radiation-induced mouse lymphoma following treatment with antitumor drugs. Cancer Res 1975;35:1957–62. [PubMed: 1149019]
16. Bouzani M, Karmiris T, Rontogianni D, Delimpassi S, Apostolidis J, Mpakiri M, Nikiforakis E. Disseminated intravascular B-cell lymphoma: clinicopathological features and outcome of three cases treated with anthracycline-based immunochemotherapy. Oncologist 2006;11:923–8. [PubMed: 16951396]
17. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000;6:1936–48. [PubMed: 10815919]
18. Bruserud O, Wendelboe O. Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? Expert Opin Biol Ther 2001;1:1005–16. [PubMed: 11728232]
19. Cantrell JL, Killion JJ, Kollmorgen GM. Correlations between humoral immunity and successful chemotherapy-immunotherapy. Cancer Res 1976;36:3051–7. [PubMed: 788896]
20. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, Coutant F, Metivier D, Pichard E, Aucouturier P, Pierron G, Garrido C, Zitvogel L, Kroemer G. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005;202:1691–701. [PubMed: 16365148]

21. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 2006;6:535–45. [PubMed: 16794636]
22. Chalandon Y, Mach JP, Pelegrin A, Folli S, Buchegger F. Combined radioimmunotherapy and chemotherapy of human colon carcinoma grafted in nude mice, advantages and limitations. Anticancer Res 1992;12:1131–9. [PubMed: 1503403]
23. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999;5:909–16. [PubMed: 10213228]
24. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 1996;88:1770–6. [PubMed: 8944008]
25. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol 2002;29:18–22. [PubMed: 12040530]
26. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–42. [PubMed: 11807147]
27. Correale P, Del Vecchio MT, Di Genova G, Savellini GG, La Placa M, Terrosi C, Vestri M, Urso R, Lemonnier F, Aquino A, Bonmassar E, Giorgi G, Francini G, Cusi MG. 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst 2005;97:1437–45. [PubMed: 16204693]
28. Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, Terrosi C, Mannucci S, Giorgi G, Francini G, Cusi MG. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother 2008;31:132–47. [PubMed: 18481383]
29. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol 1999;26:88–96. [PubMed: 10561023]
30. Czuczman MS. Immunochemotherapy in indolent non-Hodgkin's lymphoma. Semin Oncol 2002;29:11–7. [PubMed: 12040529]
31. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268–76. [PubMed: 10458242]
32. Del Poeta G, Ilaria Del Principe M, Buccisano F, Maurillo L, Niscola P, Venditti A, Amadori S. Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2006;6:1787–800. [PubMed: 17181492]
33. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177–86. [PubMed: 10851464]
34. DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A 1997;94:4000–4. [PubMed: 9108094]
35. Desrues B, Brichory F, Lena H, Bourguet P, Delaval P, Toujas L, Dazord L. Treatment of human lung carcinoma xenografts with a combination of 131I-labelled monoclonal antibody Po66 and doxorubicin. Cancer Immunol Immunother 1996;43:269–74. [PubMed: 9024503]
36. Desrues B, Lena H, Brichory F, Ramee MP, Toujas L, Delaval P, Dazord L. Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin. Br J Cancer 1995;72:1076–82. [PubMed: 7577450]
37. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P, Damle NK. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004;103:1807–14. [PubMed: 14615373]

38. Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 2007;21:2240–5. [PubMed: 17657218]
39. DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 2006;12:242–9. [PubMed: 16397048]
40. DiJoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR, Damle NK. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2004;10:8620–9. [PubMed: 15623646]
41. DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A, Khandke K, Armellino DC, Boghaert ER, Hamann P, Zinkewich-Peotti K, Stephens S, Weir N, Damle NK. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol Immunother 2005;54:11–24. [PubMed: 15693135]
42. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850–4. [PubMed: 12242449]
43. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002;25:243–51. [PubMed: 12000866]
44. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346–57. [PubMed: 15800326]
45. Dunussi-Joannopoulos K. The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma. Leuk Lymphoma 2002;43:2075–82. [PubMed: 12533031]
46. Dunussi-Joannopoulos K, Krenger W, Weinstein HJ, Ferrara JL, Croop JM. CD8+ T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment. Blood 1997;89:2915–24. [PubMed: 9108412]
47. Ehrke MJ. Immunomodulation in cancer therapeutics. Int Immunopharmacol 2003;3:1105–19. [PubMed: 12860167]
48. Emens LA, Reilly RT, Jaffee EM. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer 2005;12:1–17. [PubMed: 15788636]
49. Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 2004;6:R275–83. [PubMed: 15217493]
50. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53:4637–42. [PubMed: 8402640]
51. Fioretti MC, Bianchi R, Romani L, Bonmassar E. Drug-induced immunogenic changes of murine leukemia cells: dissociation of onset of resistance and emergence of novel immunogenicity. J Natl Cancer Inst 1983;71:1247–51. [PubMed: 6581361]
52. Fioretti MC, Romani L, Bonmassar E. Antigenic changes related to drug action. Prog Clin Biol Res 1983;132B:435–45. [PubMed: 6634765]
53. Gabrilovich DI. Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol 2007;8:2–3. [PubMed: 17196504]

54. Gamrekelashvili J, Kruger C, von Wasielewski R, Hoffmann M, Huster KM, Busch DH, Manns MP, Korangy F, Greten TF. Necrotic tumor cell death in vivo impairs tumor-specific immune responses. J Immunol 2007;178:1573–80. [PubMed: 17237406]
55. Ghiringhelli F, Apetoh L, Housseau F, Kroemer G, Zitvogel L. Links between innate and cognate tumor immunity. Curr Opin Immunol 2007;19:224–31. [PubMed: 17303400]
56. Giampietri A, Fioretti MC, Goldin A, Bonmassar E. Drug-mediated antigenic changes in murine leukemia cells: antagonistic effects of quinacrine, an antimutagenic compound. J Natl Cancer Inst 1980;64:297–301. [PubMed: 6928222]
57. Gold DV, Schutsky K, Modrak D, Cardillo TM. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res 2003;9:3929S–37S. [PubMed: 14506191]
58. Gomez GG, Hutchison RB, Kruse CA. Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. Cancer Treat Rev 2001;27:375–402. [PubMed: 11908930]
59. Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL, Gooley TA, Bush SA, Durack LD, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002;99:3158–62. [PubMed: 11964278]
60. Graeven U, Kremer B, Sudhoff T, Killing B, Rojo F, Weber D, Tillner J, Unal C, Schmiegel W. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 2006;94:1293–9. [PubMed: 16622465]
61. Han HD, Song CK, Park YS, Noh KH, Kim JH, Hwang T, Kim TW, Shin BC. A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine. Int J Pharm 2008;350:27–34. [PubMed: 17897800]
62. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991;51:4575–80. [PubMed: 1678683]
63. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Griffiths R, Steven N, Hawkins RE. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-Xuorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 2008;57:977–86. [PubMed: 18060404]
64. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Melcher A, Nicholls J, Wassan H, Habib N, Anthoney A. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007;13:4487–94. [PubMed: 17671134]
65. Hayakawa M, Kawaguchi S, Ishii S, Murakami M, Uede T. B7-1-transfected tumor vaccine counteracts chemotherapy-induced immunosuppression and prolongs the survival of rats bearing highly metastatic osteosarcoma cells. Int J Cancer 1997;71:1091–102. [PubMed: 9185716]
66. Head JF, Elliott RL, McCoy JL. Evaluation of lymphocyte immunity in breast cancer patients. Breast Cancer Res Treat 1993;26:77–88. [PubMed: 8400326]
67. Hou JM, Liu JY, Yang L, Zhao X, Tian L, Ding ZY, Wen YJ, Niu T, Xiao F, Lou YY, Tan GH, Deng HX, Li J, Yang JL, Mao YQ, Kan B, Wu Y, Li Q, Wei YQ. Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities. Oncology 2005;69:81–7. [PubMed: 16088235]
68. Houchens DP, Bonmassar E, Gaston MR, Kende M, Goldin A. Drug-mediated immunogenic changes of virus-induced leukemia in vivo. Cancer Res 1976;36:1347–52. [PubMed: 1260759]
69. Jeglum KA, Young KM, Barnsley K, Whereat A. Chemotherapy versus chemotherapy with intralymphatic tumor cell vaccine in canine lymphoma. Cancer 1988;61:2042–50. [PubMed: 3359402]
70. Kang TH, Lee JH, Song CK, Han HD, Shin BC, Pai SI, Hung CF, Trimble C, Lim JS, Kim TW, Wu TC. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res 2007;67:802–11. [PubMed: 17234792]

71. Kievit E, Pinedo HM, Schluper HM, Boven E. Addition of cisplatin improves efficacy of 131I-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer. Int J Radiat Oncol Biol Phys 1997;38:419–28. [PubMed: 9226331]
72. Kim CH, Woo SJ, Park JS, Kim HS, Park MY, Park SD, Hong YK, Kim TG. Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology 2007;122:615–22. [PubMed: 17645496]
73. Kipp RT, McNeel DG. Immunotherapy for prostate cancer - recent progress in clinical trials. Clin Adv Hematol Oncol 2007;5:465–74. 77–9. [PubMed: 17679921]
74. Ko AH. Future strategies for targeted therapies and tailored patient management in pancreatic cancer. Semin Oncol 2007;34:354–64. [PubMed: 17674964]
75. Ko EC, Wang X, Ferrone S. Immunotherapy of malignant diseases. Challenges and strategies. Int Arch Allergy Immunol 2003;132:294–309. [PubMed: 14707461]
76. Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY, Sakaguchi S, Kang CY. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007;67:7477–86. [PubMed: 17671218]
77. Kofler DM, Mayr C, Wendtner CM. Current status of immunotherapy in B cell malignancies. Curr Drug Targets 2006;7:1371–4. [PubMed: 17073599]
78. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 2001;61:8105–9. [PubMed: 11719436]
79. Krysko DV, D'Herde K, Vandenabeele P. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 2006;11:1709–26. [PubMed: 16951923]
80. Lake RA, Robinson BW. Immunotherapy and chemotherapy--a practical partnership. Nat Rev Cancer 2005;5:397–405. [PubMed: 15864281]
81. Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, Mineur P, Bennett JM, Berger MS, Eten CB, Munteanu M, Loken MR, Van Dongen JJ, Bernstein ID, Appelbaum FR. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002;16:1627–36. [PubMed: 12200674]
82. Liu JY, Wu Y, Zhang XS, Yang JL, Li HL, Mao YQ, Wang Y, Cheng X, Li YQ, Xia JC, Masucci M, Zeng YX. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother 2007;56:1597–604. [PubMed: 17440723]
83. Luftner D, Pollmann D, Schildhauer S, Sehouli J, Possinger K. Perspectives of immunotherapy in metastatic breast cancer. Anticancer Res 2005;25:4599–604. [PubMed: 16334149]
84. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4 (+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862–8. [PubMed: 15591121]
85. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001;61:3689–97. [PubMed: 11325840]
86. Markasz L, Skribek H, Uhlin M, Otvos R, Flaberg E, Eksborg S, Olah E, Stuber G, Szekely L. Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. J Immunother 2008;31:283–93. [PubMed: 18317359]
87. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265–74. [PubMed: 15911866]
88. Masters GR, Berger MA, Albone EF. Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts. Gynecol Oncol 2006;102:462–7. [PubMed: 16434088]

89. McMillin DW, Hewes B, Gangadharan B, Archer DR, Mittler RS, Spencer HT. Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy. Hum Gene Ther 2006;17:798–806. [PubMed: 16942440]

90. Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008;57:1579–87. [PubMed: 18369619]

91. Mihich E. Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice. Cancer Res 1969;29:848–54. [PubMed: 4887203]

92. Mihich E. Modification of tumor regression by immunologic means. Cancer Res 1969;29:2345–50. [PubMed: 5387264]

93. Mihich E. Preclinical evaluation of the interrelationships between cancer chemotherapy and immunity. Natl Cancer Inst Monogr 1971;34:90–102. [PubMed: 4400958]

94. Mihich E. Anticancer drug-induced immunomodulation and cancer therapeutics. Curr Cancer Ther Rev 2007;3:174–93.

95. Mitchell MS. Combinations of anticancer drugs and immunotherapy. Cancer Immunol Immunother 2003;52:686–92. [PubMed: 12942200]

96. Mitchell MS. Immunotherapy as part of combinations for the treatment of cancer. Int Immunopharmacol 2003;3:1051–9. [PubMed: 12860162]

97. Mokyr MB, Dray S. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide. Cancer Res 1983;43:3112–9. [PubMed: 6850619]

98. Mokyr MB, Hengst JC, Dray S. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors. Cancer Res 1982;42:974–9. [PubMed: 6977410]

99. Motoyoshi Y, Kaminoda K, Saitoh O, Hamasaki K, Nakao K, Ishii N, Nagayama Y, Eguchi K. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 2006;16:141–6. [PubMed: 16786137]

100. Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP. Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol 2006;3:668–81. [PubMed: 17139318]

101. Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW. Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Rev Vaccines 2006;5:381–94. [PubMed: 16827622]

102. Nicolin A, Spreafico F, Bonmassar E, Goldin A. Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide in vivo. J Natl Cancer Inst 1976;56:89–93. [PubMed: 1255754]

103. Noguchi M, Itoh K, Yao A, Mine T, Yamada A, Obata Y, Furuta M, Harada M, Suekane S, Matsuoka K. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate 2005;63:1–12. [PubMed: 15378520]

104. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA, Robinson BW. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003;170:4905–13. [PubMed: 12734333]

105. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003;63:4490–6. [PubMed: 12907622]

106. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54–61. [PubMed: 17187072]

107. Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P, Ghiringhelli F, Apetoh L, Chaput N, Flament C, Ullrich E, de Botton S, Zitvogel L, Kroemer G. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev 2007;220:22–34. [PubMed: 17979837]

108. Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R, Peruzzotti G, Goldhirsch A, Pietri E, Colleoni M. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006;6:225. [PubMed: 16978400]

109. Park SD, Kim CH, Kim CK, Park JA, Sohn HJ, Hong YK, Kim TG. Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. Vaccine 2007;25:3485–91. [PubMed: 17275143]
110. Paul AR, Engstrom PF, Weiner LM, Steplewski Z, Koprowski H. Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM). Hybridoma 1986;5(Suppl 1):S171–4. [PubMed: 3527946]
111. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241–51. [PubMed: 10327070]
112. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659–71. [PubMed: 9704716]
113. Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 1999;26:89–95. [PubMed: 10482199]
114. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–72. [PubMed: 16236737]
115. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829–38. [PubMed: 7911565]
116. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235–49. [PubMed: 9811454]
117. Pinkerton R. Continuing challenges in childhood non-Hodgkin's lymphoma. Br J Haematol 2005;130:480–8. [PubMed: 16098061]
118. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD, Martin PJ, Fisher DR, Wood B, Borrow JW, Porter B, Smith JP, Matthews DC, Appelbaum FR, Bernstein ID. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000;96:2934–42. [PubMed: 11049969]
119. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143–9. [PubMed: 16896003]
120. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003;102:1606–12. [PubMed: 12738671]
121. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMCC225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994–1003. [PubMed: 12006511]
122. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002;99:2310–4. [PubMed: 11895761]
123. Ravindranath MH, Muthugounder S, Presser N, Viswanathan S. Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol 2004;546:121–65. [PubMed: 15584372]
124. Reiter I, Krammer B, Schwamberger G. Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities. J Immunol 1999;163:1730–2. [PubMed: 10438900]

125. Romani L, Fioretti MC, Bonmassar E. In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo. Transplantation 1979;28:218–22. [PubMed: 494379]

126. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr. Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–84. [PubMed: 16236738]

127. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004;101(Suppl 2):14639–45. [PubMed: 15381769]

128. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474–84. [PubMed: 2679456]discussion 84-5

129. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159–66. [PubMed: 8028037]

130. Samanta S, Alam SM, Basu S, Maji T, Roy DK, Jha T. Chemoimmunotherapeutic approach to prolonged survival time in combination with immunization and glutamic Acid derivatives with antitumor activity in tumor-bearing mice. Biol Pharm Bull 2007;30:2334–9. [PubMed: 18057722]

131. Sato Y, Fujiwara T, Mine T, Shomura H, Homma S, Maeda Y, Tokunaga N, Ikeda Y, Ishihara Y, Yamada A, Tanaka N, Itoh K, Harada M, Todo S. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci 2007;98:1113–9. [PubMed: 17459063]

132. Schuster M, Nechansky A, Kircheis R. Cancer immunotherapy. Biotechnol J 2006;1:138–47. [PubMed: 16892244]

133. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. Int J Cancer 2001;94:243–51. [PubMed: 11668505]

134. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001;7:1204–13. [PubMed: 11350885]

135. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999;93:3678–84. [PubMed: 10339474]

136. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19:3244–54. [PubMed: 11432892]

137. Sinkovics JG, Horvath JC. Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts. Int J Oncol 2006;29:765–77. [PubMed: 16964374]

138. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92. [PubMed: 11248153]

139. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29–36. [PubMed: 17208639]

140. Song CK, Han HD, Noh KH, Kang TH, Park YS, Kim JH, Park ES, Shin BC, Kim TW. Chemotherapy enhances CD8(+) T cell-mediated antitumor immunity induced by vaccination with vaccinia virus. Mol Ther 2007;15:1558–63. [PubMed: 17551502]
141. Tan GH, Tian L, Wei YQ, Zhao X, Li J, Wu Y, Wen YJ, Yi T, Ding ZY, Kan B, Mao YQ, Deng HX, Li HL, Zou CH, Fu CH. Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities. Int J Cancer 2004;112:701–6. [PubMed: 15382054]
142. Tschmelitsch J, Barendswaard E, Williams C Jr. Yao TJ, Cohen AM, Old LJ, Welt S. Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res 1997;57:2181–6. [PubMed: 9187118]
143. Untch M, Ditsch N, Hermelink K. Immunotherapy: new options in breast cancer treatment. Expert Rev Anticancer Ther 2003;3:403–8. [PubMed: 12820782]
144. van den Eertwegh AJ. Active specific immunotherapy in colon cancer. Recent Results Cancer Res 2005;165:260–7. [PubMed: 15865042]
145. van der Most RG, Currie A, Robinson BW, Lake RA. Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 2006;66:601–4. [PubMed: 16423984]
146. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389–97. [PubMed: 11208830]
147. Voso MT, Pantel G, Weis M, Schmidt P, Martin S, Moos M, Ho AD, Haas R, Hohaus S. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000;109:729–35. [PubMed: 10929022]
148. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004;10:5316–26. [PubMed: 15328167]
149. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004;22:2610–6. [PubMed: 15226328]
150. Yanagimoto H, Mine T, Yamamoto K, Satoi S, Terakawa N, Takahashi K, Nakahara K, Honma S, Tanaka M, Mizoguchi J, Yamada A, Oka M, Kamiyama Y, Itoh K, Takai S. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 2007;98:605–11. [PubMed: 17309598]
151. Yang S, Haluska FG. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J Immunol 2004;172:4599–608. [PubMed: 15034078]
152. Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, Kranz DM, Schreiber H. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007;204:49–55. [PubMed: 17210731]
153. Zheng SJ, Zheng SP, Huang FY, Jiao CL, Wu RL. Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model. World J Gastroenterol 2007;13:2484–9. [PubMed: 17552033]
154. Zheng SP, Zheng SJ, Wu RL, Huang FY, Cao LM, Jiao CL. Enhanced efficacy in anti-tumour activity by combined therapy of recombinant FGFR-1 related angiogenesis and low-dose cytotoxic agent. Eur J Cancer 2007;43:2134–9. [PubMed: 17720490]
155. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8:59–73. [PubMed: 18097448]

Table 1

Effect of combined mAb IT and CT on tumor growth and/or survival in mice

Tumor type	mAb IT				CT				Temporal relationship between IT and CT	Effect of combined therapy on		Possible mechanism of tumor growth inhibition		Ref.
	Designation (Specificity)	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration		Growth of established tumor	Survival after tumor challenge	IT	CT	
Human colon carcinoma	^{131}I-A33 (A33 Ag)	0.1 mCi/mouse	1 ×	i.v.	5-FU or 5-FU + leucovorin, DOX, or carmustine	0.75 - 75 mg/kg	2 × or 5 ×	i.p.	IT and CT simultaneously	Inhibition	NT	Radiation	Apoptosis	[142]
Human acute lymphoblastic leukemia	CMC-544 conjugated to calicheamicin (CD22)	80-160 μg/kg	3 ×	i.p.	Calicheamicin	160 μg/kg	3 ×	i.p.	IT and CT simultaneously	Inhibition	Enhancement	Tumor-targeted delivery of cytotoxic agent	Apoptosis	[37,38, 40,41]
Human B-cell non-Hodgkin's lymphoma	CMC-544 conjugated to calicheamicin (CD22)	80-160 μg/kg	3 ×	i.p.	Calicheamicin	80-160 μg/kg	3 ×	i.p.	IT and CT simultaneously	Inhibition	Enhancement	Tumor-targeted delivery of cytotoxic agent ADCC and CDC	Apoptosis	[39]
	Rituximab (CD20)	20 mg/kg	3 ×	i.p.										
Murine mesothelioma	FGK45 (CD40)	100 μg/mouse	3 ×	i.v.	Gemcitabine	120 μg/g	5 ×	i.p.	IT and CT simultaneously	Inhibition	Enhancement	Activation ofDC	Apoptosis, activation of$CD4^+$ and $CD8^+$ T cells	[105]
Murine sarcoma cells (AG104)	Anti-CD137 (CD137)	200 μg/mouse	2 ×	i.p.	TMTX	17.5 mg/kg	5 ×	i.p.	CT 4 days after IT	Inhibition	Enhancement	Activation of T-cell responses	Apoptosis	[89]
Human colon carcinoma	^{131}I-F(ab')2-35, CE25, B17andB93 (CEA)	800 or 1600 μCi/mouse	1 or 2 ×	i.v.	5-FU	40 mg/kg	5 ×	i.p.	CT before, simultaneously and after IT	Inhibition	NT	Radiation	Apoptosis and radiosensitization	[22]
Human breast cancer	90Y-Chimeric L6 (undefined integral membrane glycoprotein)	260 μCi/mouse	l ×	i.v.	TAX	600 μg/mouse	1 ×	i.p.	CT 1 day after IT	Inhibition	NT	Radiation	Apoptosis	[34]
Human breast adenocarcinoma cell &	528 & 225 (EGFR)	1 mg/mouse	10 ×	i.p.	DOX	50-100 μg/mouse	2 ×	i.p.	IT and CT simultaneously	Inhibition	Enhancement	Blockade of EGF-R activation	Apoptosis, increase in EGF-R expression	[9]

Tumor type	mAb IT				CT				Temporal relationship between IT and CT	Effect of combined therapy on		Possible mechanism of tumor growth inhibition		Ref.
	Designation (Specificity)	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration		Growth of established tumor	Survival after tumor challenge	IT	CT	
squamous carcinoma cell														
Human colon carcinoma	C225 (EGF-R)	0.25 mg/kg	10 ×	i.p.	8-Cl-cAMP	0.5 mg/mouse	10 ×	i.p.	IT and CT simultaneously	Inhibition	Enhancement	Blockade of EGF-R activation	Inhibition of cAMP-dependent PKAIand TGF-α	[24]
Human colon carcinoma	C225 (EGF-R)	0.25 mg/kg	10 ×	i.p.	Topotecan	2 mg/kg	4 ×	i.p.	IT and CT simultaneously	Inhibition	Enhancement	Blockade of EGF-R activation	Inhibition of topoisomerase	[23]
Human colon carcinoma	C225 (EGF-R)	1 mg/mouse	14 ×	i.p.	Irinotecan	100-150 mg/kg	7 ×	i.p.	CT 3 days before IT	Inhibition	NT	Blockade of EGF-R activation	Apoptosis	[121]
Human colon carcinoma	C225 (EGF-R)	1 mg/mouse	7 ×	i.p.	Oxalipatin	10 mg/kg	1 ×	i.v.	IT and CT simultaneously	Inhibition	NT	Blockade of EGF-R activation	Apoptosis	[7]
Human epidermoid carcinoma	225 and 528 (EGF-R)	1 mg/mouse	8 ×	i.p.	*cis*-diamminedich loroplatinum	6 mg/kg	2 ×	i.p.	IT and CT simultaneously	Inhibition	Enhancement	Blockade of EGF-R activation	Apoptosis	[50]
Human pancreatic cancer	C225 (EGF-R)	1 mg/mouse	2 ×	i.p.	Gemcitabine	250 mg/kg	2 ×	i.p.	IT 1 day before CT	Inhibition	NT	Blockade of EGF-R activation	Apoptosis	[17]
Human ovarian cancer	^{131}I-323/A3 (EGP40)	200 μCi/mouse	2 ×	i.v.	CDDP	4 mg/kg	2 ×	i.v.	CT 1 day after IT	Inhibition	NT	Radiation	Apoptosis	[71]
Human breast cancer	Herceptin (HER2)	0.3 mg/kg	10 ×	i.p.	TAX	10 mg/kg	2 ×	i.v.	TAX on days 1 and 4 of IT	NT	Enhancement	HER-2 downregulation by Ab, leading to cell growth inhibition by increased susceptibility to	Inhibition of cell division by tubulin polymerizat ion	[8]

Tumor type	mAb IT				CT				Temporal relationship between IT and CT	Effect of combined therapy on		Possible mechanism of tumor growth inhibition		Ref.
	Designation (Specificity)	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration		Growth of established tumor	Survival after tumor challenge	IT	CT	
												CT; or HER-2 upregulation by TAX leading to Herceptin-mediated apoptosis of tumor cells		
					DOX	10 mg/kg	1 ×	i.p.	DOX on day 1 of IT					
Human breast cancer	4D5 (HER- 2)	1 or 3 mg/kg	3 ×	i.p.	CDDP	0.25 or 0.75 mg/kg	1 ×	i.p.	CT immediately after IT	Inhibition	NT	HER-2 downregulation, leading to cell growth inhibition by increased susceptibility to CT	Apoptosis	[116]
Human breast cancer	Rhu mAb (HER2)	4-10mg/kg	1 or 2 ×	i.p.	MTX	2 mg/kg	2 ×	i.p.	IT and CT simultaneously	Inhibition	NT	HER-2 downregulation, leading to cell growth inhibition by increased susceptibility to CT	Apoptosis	[111]
					VP-16	20 mg/kg	2 ×							
					5-FU	16 mg/kg	2 ×							
					VBL	0.8 mg/kg	2 ×							
					DOX	5 mg/kg	1 ×							
					CY	80 mg/kg	3 ×							
					TAX	15 mg/kg	3 ×							
Human prostate cancer	Herceptin (HER2-neu)	20 mg/kg	6 ×	i.p.	TAX	6.25 mg/kg	15 ×	s.c.	IT and CT simultaneously	Inhibition	NT	HER-2 downregulation, leading to cell growth inhibition by increased	Inhibition of cell division by tubulin polymerizetion	[1]

Tumor type	mAb IT				CT				Temporal relationship between IT and CT	Effect of combined therapy on		Possible mechanism of tumor growth inhibition		Ref.
	Designation (Specificity)	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration		Growth of established tumor	Survival after tumor challenge	IT susceptibility to CT	CT	
Human lung carcinoma	^{131}I-Po66 (undefined intracellular Ag)	250 μCi/mouse	3 ×	i.v.	DOX	8 mg/kg	2 ×	i.v.	IT 1 day after CT	Inhibition	NT	Radiation	Apoptosis and enhanced accessibility of Ag for mAb	[35,36]
Human ovarian cancer	^{90}Y-DOTA 776.1 (CA 125)	50 or 150 μCi/mouse	1 ×	i.v.	TAX	10 mg/kg	1 ×	i.p.	IT 1 day after CT	Inhibition	NT	Radiation	Apoptosis	[88]
Human pancreatic cancer	^{90}Y-PAM4 (MUC1)	25 μCi/mouse	3 ×	i.v.	Gemcitabine	1000 mg/m^2	9 ×	i.p.	IT1 day before CT IT and CT simultaneously	Inhibition Inhibition	NT Enhancement	Radiation	Apoptosis, radiosensitization of tumor cells	[57]

Abbreviations: 5-FU, 5-fluorouracil; Ag, antigen; CDDP, cisplatin; CEA, carcinoembryonic antigen; CPA, cyclophosphamide; CT, chemotherapy; CY, cydophosphamide; DC, dendritic cells; DOX, Doxorubicin; EGF-R, epidermal growth factor receptor; EGP40, epithelial glycoprotein 40; i.p., intraperitoneally; IT, immunotherapy; i.v., intravenously; mAb, monoclonal antibody; MTX, Methotrexate; NT, not tested; PKA, protein kinase; s.c., subcutaneously; TAX, paclitaxel; TGF, transforming growth factor; TMTX, antifolate trimetrexate;VBL, vinca alkaloid vinblastine; VP-16, Topoisomerase II inhibitor etoposide

Table 2

Clinical trials of combined mAb IT and CT

Tumor type	mAb IT				CT				Temporal relationship between IT & CT	No. of patients	Clinical outcome (No. of patients)	Possible mechanism of therapeutic effect		Ref.
	Designation (specificity)	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration				mAb	CT	
Pancreatic carcinoma	17-1A	400 mg/patient	1 ×	i.v.	5-FU	600 mg/m^2	4 ×	i.v.	CT 1 day after IT	8	PR: 2 NR: 6	ADCC, idiotypic network	Apoptosis	[110]
					adriamycin	30 mg/m^2	2 ×	i.v.						
					mitomycin	10 mg/m^2	1 ×	i.v.						
B-cell lymphoma	Rituximab (CD20)	375 mg/m^2	6 ×	i.v.	CY	750 mg/m^2	6 ×	i.v.	CT 7 days after IT	38	CR: 22 PR: 16	ADCC, CDC, apoptosis by crosslinking of CD20	Apoptosis	[29-31]
					Dox	50 mg/m^2	6 ×	i.v.						
					vincristine	1.4 mg/m^2	6 ×	i.v.						
					prednisone	100 mg/m^2	30 ×	p.o.						
B-cell lymphoma	^{131}I-tositumomab (CD20)	1.7 mg/kg (20-27 Gy)	1-4 ×	i.v.	Etoposide	60 mg/kg	1-4 ×	i.v.	CT 2 days after radio-IT	31	CR: 24 PR: 3	Radiation, apoptosis by crosslinking of CD20	Apoptosis	[118]
					CY	100 mg/kg	1-4 ×	i.v.			SD: 2 PD: 1			
B-cell lymphoma	Rituximab (CD20)	375 mg/m^2	6 ×	i.v.	CY	750 mg/m^2	6-8 ×	i.v.	IT and CT simultaneously	3	CR: 3	ADCC, CDC, apoptosis by crosslinking of CD20	Apoptosis	[16]
					Dox	50 mg/m^2	6-8 ×	i.v.						
					vincristine	1.4 mg/m^2	6-8 ×	i.v.						
					prednisone	100 mg/m^2	30-40 ×	p.o.						
					MTX	15 mg/m^2	8 ×	i.v.						
Non-Hodgkin's lymphoma	Rituximab (CD20)	375 mg/m^2	4 ×	i.v.	CY	750 mg/m^2	3 ×	i.v.	CT 1 day after IT	18	CR: 7 PR: 10 PD: 1	ADCC, CDC, apoptosis by crosslinking of CD20	Apoptosis, mobilization of peripheral blood stem cells	[147]
					Dox	50 mg/m^2	3 ×	i.v.						
					vincristine	1.4 mg/m^2	3 ×	i.v.						
					prednisone	100 mg/m^2	15 ×	p.o.						
					Cytosine arabinoside	2000 mg/m^2	4 ×	i.v.						

Tumor type	mAb IT				CT				Temporal relationship between IT & CT	No. of patients	Clinical outcome (No. of patients)	Possible mechanism of therapeutic effect		Ref.
	Designation (specificity)	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration				mAb	CT	
					mitoxantrone	10 mg/m^2	2 ×	i.v.						
Non-Hodgkin's Lymphoma	Rituximab (CD20)	375 mg/m^2	6 ×	i.v.	CY	750 mg/m^2	6-8 ×	i.v.	CT 1 day after IT	33	CR: 20 PR: 11 PD: 2	ADCC, CDC, apoptosis by crosslinking of CD20	Apoptosis	[146]
					Dox	50 mg/m^2	6-8 ×	i.v.						
					vincristine	1.4 mg/m^2	6-8 ×	i.v.						
					prednisone	100 mg/m^2	30-40 ×	p.o.		202	CR: 152 PR: 15 SD: 2 PD: 31 NA: 2			[25,26]
Non-Hodgkin's Lymphoma	^{131}I-tositumomab (CD20)	5-10 mCi	2 ×	i.v.	CY	750 mg/m^2	6 ×	i.v.	CT 30 to 60 days after Radio-IT	90	CR: 62 PR: 20 SD: 2 NA: 6	Radiation, apoptosis by crosslinking of CD20	Apoptosis	[119,120]
					Dox	50 mg/m^2	6 ×	i.v.						
					vincristine	1.4 mg/m^2	6 ×	i.v.						
					prednisone	100 mg/m^2	30 ×	p.o..						
MCL	^{131}I-tositumomab (CD20)	5-10 mCi (1.7 mg/kg)	2 ×	i.v.	Etoposide	30-60 mg/kg	1 ×	i.v.	CT 10 days after IT	11	CR: 8 PR: 1 NR: 2	Radiation, apoptosis by crosslinking of CD20	Apoptosis	[59]
					CY	60-100 mg/kg	1 ×	i.v.						
Acute myeloid leukemia	CMA-676 linked to calicheamicin (CD33)	9 mg/m^2	2 ×	i.v.	Calicheamicin	9 mg/m^2	2 ×	i.v.	IT and CT simultaneously	142	CR: 23 CRp: 19 NR: 100	Tumor-targeted delivery of cytotoxic agent	Apoptosis	[122,135,136]
Acute myeloid leukemia	Gemtuzumab linked to calicheamicin (CD33)	9 mg/m^2	2 ×	i.v.	Calicheamicin	9 mg/m^2	2 ×	i.v.	IT and CT simultaneously	101	CR: 13 CRp: 15 NR: 73	Tumor-targeted delivery of cytotoxic agent	Apoptosis	[81]
Head and neck cancer	C225 (EGFR)	250 and 400 mg/m^2	6 ×	i.v.	Cisplatin	100 mg/m^2	2 ×	i.v.	CT 1 day after IT	9	CR: 2 PR: 4 PD: 3	Inhibition of tumor cell proliferation by EGFR blockade.	Apoptosis	[134]
Small cell lung cancer, head and neck cancer	C225 (EGFR)	200 and 400 mg/m^2	12 ×	i.v.	Cisplatin	60 mg/m^2	3 ×	i.v.	CT 1 day after IT	22	CR: 1 PR: 2 SD: 11 PD: 8	EGFR blockade	Apoptosis	[10]

Tumor type	mAb IT				CT				Temporal relationship between IT & CT	No. of patients	Clinical outcome (No. of patients)	Possible mechanism of therapeutic effect		Ref.
	Designation (specificity)	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration				mAb	CT	
Squamous cell carcinoma of the head and neck	Cetuximab (EGFR)	250 and 400 mg/m^2	3-4 ×	i.v.	Cisplatin	60 mg/m^2	2-4 ×	i.v.	CT 1 hour after IT	96	PR: 10 SD: 41 PD: 27 NA: 14 Missing: 4	EGFR blockade	Apoptosis	[11].
					Carboplatin	250 mg/m^2	2-4 ×	i.v.						
Pancreatic cancer	Cetuximab (EGFR)	250 and 400 mg/m^2	7-90 ×	i.v.	Gemcitabine	1000 mg/m^2	7-90 ×	i.v.	IT and CT simultaneously	41	PR: 5 SD: 26 PD: 6 NA: 4	EGFR blockade	Apoptosis	[149]
Pancreatic cancer	Matuzumab (EGFR)	400 or 800 mg/m^2	8 ×	i.v.	Gemcitabine	1000 mg/m^2	6 ×	i.v.	IT and CT simultaneously	12	PR: 3 SD: 5 PD: 4	EGFR blockade	Apoptosis	[60]
Breast cancer	Trastuzumab/Herceptin (HER-2)	100 or 250 mg/patient	9 ×	i.v.	CDDP	75 mg/m^2	3 ×	i.v.	CT 1 day after IT	37	PR: 9 SD: 9 PD: 19	Inhibition of tumor cell proliferation by downregulation of HER-2 receptor	Apoptosis	[112,113]
Breast cancer	Trastuzumab (HER-2)	4 or 2 mg/kg	40 ×	i.v.	Dox	60 mg/m^2	80 ×	i.v.	CT 7 days after IT	235	CR: 18 PR: 100 PD: 117	Inhibition of tumor cell proliferation by downregulation of HER-2 receptor	Apoptosis	[138]
					CY	600 mg/m^2	80 ×	i.v.						
					Epirubicin	75 mg/m^2	80 ×	i.v.						
					Paclitaxel	175 mg/m^2	80 ×	i.v.						
Breast cancer	Trastuzumab (HER-2)	4 or 2 mg/kg	<52 ×	i.v.	Paclitaxel	80-150 mg/m^2	12 ×	i.v.	IT 1 day or 10 weeks	32	CR: 5 PR: 23 SD: 4	Inhibition of tumor cell proliferation by downregulation of HER-2 receptor	Apoptosis	[14]
					Dox	60 mg/m^2	3 ×	i.v.	after CT					
Breast cancer	Trastuzumab (HER-2)	8 or 6 mg/kg	8 ×	i.v.	MTX	2.5 mg	48 ×	p.o.	IT and CT simultaneously	22	PR: 4 SD: 10 PD: 8	Inhibition of tumor cell proliferation by downregulation of HER-2 receptor	Apoptosis; low dose CY and MTX reduction of VEGF level	[108]
					CY	50 mg	180 ×	p.o.						

Tumor type	mAb IT				CT				Temporal relationship between IT & CT	No. of patients	Clinical outcome (No. of patients)	Possible mechanism of therapeutic effect		Ref.
	Designation (specificity)	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration				mAb	CT	
Breast cancer	Trastuzumab (HER-2)	4 or 2 mg/kg	52 ×	i.v.	Dox	60 mg/m^2	4 ×	i.v.	IT and CT simultaneously	1679/1 672[a]	67.1%/85.1 %[a]	Inhibition of tumor cell proliferation by downregulation of HER-2 receptor	Apoptosis	[126]
					CY	600 mg/m^2	4 ×	i.v.			4 yrs DFS			
					Paclitaxel	175 mg/m^2	4-12 ×	i.v.						
Breast cancer	Trastuzumab (HER-2)	8 or 6 mg/kg	35 ×	i.v.	Combination with DOX, CY, 5-FU, MTX, epirubicin, paclitaxel, Taxane, docetaxel	50-720 mg/m^2	>4 ×	p.o. or i.v.	NA	1693/1 694[a]	77.4%/85.8 %[a] 2 yrs DFS	Inhibition of tumor cell proliferation by downregulation of HER-2 receptor	Apoptosis	[114]
Breast cancer	Trastuzumab (HER-2)	8 or 6 mg/kg	52 ×	i.v.	Combination with DOX, CY, 5-FU, MTX, epirubicin, paclitaxel, Taxane, docetaxel	50-720 mg/m^2	> 4×	p.o. or i.v.	NA	1698/1 703[a]	74.3%/80.6 %[a] 3 yrs DFS	Inhibition of tumor cell proliferation by downregulation of HER-2 receptor	Apoptosis	[139]
Breast cancer	Trastuzumab (HER-2)	4 or 2 mg/kg	30-200 ×	i.v.	Dox	100 mg/m^2	> 6 ×	i.v.	NA	92	CR: 6 PR: 50 SD: 25 PD: 11	Inhibition of tumor cell proliferation by downregulation of HER-2 receptor	Apoptosis	[87]

Abbreviations: 5-FU, 5-fluorouracil; ADCC, antibody-dependent cell-mediated cytotoxicity; CDC, completment-dependent cytotoxicity; CDDP, cisplatin; CR, complete response; CRp, remission with incomplete platelet recovery; CT, chemotherapy; CY, cyclophosphamide; DFS, disease-free survival; Dox, Doxorubicin; IT, immunotherapy; i.v., intravenously; MCL, Mantle cell lymphoma; MTX, methotrexate; NA, no assessment; NR, no response; PD, progressive disease; p.o., per os; PR, partial response; SD, stable disease.

[a] CT/CT+IT

Table 3

Effect of combined active specific IT and CT on tumor growth and/or survival in experimental animals

Tumor type	Vaccine IT				CT				Temporal relationship between IT and CT	Effect of combined therapy on		Possible mechanism of tumor growth inhibition		Ref.
	Composition	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration		Growth of established tumor	Survival after tumor challenge	IT	CT	
Murine AML	Irradiated, B7.1-transduced AML cells	10^5 cells/mouse	1 ×	i.v.	Ara-C	200 mg/kg	3 ×	i.p.	IT 8 days after CT	NT	Enhancement	$CD8^+$CTL response against AML cells	Apoptosis	[46]
Human breast carcinoma-derived Ehrlich Ascites Carcinoma, EAC)	Irradiated EAC cells or cell extract	4×10^5 cells/10g body weight	5 ×	i.p.	Derivatives and analogs of glutamine and glutamic acid	50 mg/kg	5 ×	i.p.	IT and CT simultaneously	NT	Enhancement	NT	Apoptosis	[130]
	Irradiated EAC cells or cell extract	4×10^5 cells/10g body weight	5 ×	i.p.	Etoposide	2.5 mg/kg	5 ×	i.p.	IT and CT simultaneously	NT	Enhancement	NT	Apoptosis	
Murine breast cancer	Ad-sig-TAA/ecd CD40L infected DCs	5 × 105 mouse	1 ×	i.t.	5-FC	500 mg/kg	10 ×	i.p.	IT 3 days after CT	Inhibition	Enhancement	Tumor-specific CTL	Apoptosis	[2]
Murine breast cancer	SINCP-HER2/neu plasmid	100 μg/mouse	3 ×	i.m.	DOX	5 mg/kg	1 ×	i.v.	IT 1 day after CT	Inhibition	NT	NT	Apoptosis	[49]
	SINCP-HER2/neu plasmid	100 μg/mouse	3 ×	i.m.	Paclitaxel	25 mg/kg	1 ×	i.p.	IT 1 day after CT	No effect	NT	NT	Apoptosis	
	VRP-HER2/neu	10^6 infectious units/mouse	3 ×	Foot pad	DOX	5 mg/kg	1 ×	i.v.	IT 1 day after CT	Inhibition	NT	$CD8^+$ CTL response	Apoptosis, enhancement of immune responses	
	VRP-HER2/neu	10^6 infectious units/mouse	3 ×	Foot pad	Paclitaxel	25 mg/kg	1 ×	i.p.	IT 1 day after CT	Inhibition	NT	$CD8^+$ CTL response	Apoptosis, enhancement of immune responses	
Murine breast cancer	Irradiated HER2/neu + GM-CSF transduced 3T3 cells	3×10^6 cells/mouse	8 ×	s.c.	DOX	5 mg/kg	2 ×	i.v.	IT 1 day after CT	Inhibition	NT	Th1 T-cell response	Apoptosis	[85]
									IT 7 days before CT	Inhibition	NT		Apoptosis	
					Paclitaxel	20 mg/kg	2 ×	i.p.	IT 1 day after CT	Inhibition	NT		Apoptosis, enhancement of Th1 T-cell	

Tumor type	Vaccine IT				CT				Temporal relationship between IT and CT	Effect of combined therapy on		Possible mechanism of tumor growth inhibition		Ref.
	Composition	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration		Growth of established tumor	Survival after tumor challenge	IT	CT	
													response	
									IT 7 days before CT	Inhibition	NT		Apoptosis, inhibition of Th1 T-cell response	
					CY	100 mg/kg	2 ×	i.p.	IT 1 day after CT	Inhibition	NT		Apoptosis, enhancement of Th1 T-cell response	
									IT 7 days before CT	Inhibition	NT		Apoptosis, inhibition of Th1 T-cell response	
Canine lymphoma	Irradiated lymphoma cells	10^8 cells/mouse	3 ×	Intralymphatically	Vincristine CY	0.03 mg/kg	2 ×	i.v.	IT 2 weeks after CT	NT	Enhancement	NT	CY: enhancement of immune response;	[69]
						10 mg/kg	2 ×	i.v.						
					L-asparag inase	400 IU/kg	2 ×	i.p.						
					DOX	30 mg/m^2	2 ×	i.v.					Other CT agents: Apoptosis	
Murine cervical carcinoma (HPV-16 E7-expressing TC-1)	Vaccinia virus-encoding Sig/E7/L AMP-1	3×10^6 pfu/mouse	1 ×	i.p.	Epigallocatechin-3-gallate	0.5 mg/ml	5 ×	p.o.	CT 3 days after IT	Inhibition	NT	$CD8^+$ CTL response	Apoptosis, enhancement of Ag-specific $CD8^+$ CTL response	[70,140]
	Vaccinia virus-encoding Sig/E7/L AMP-1	3×10^6 pfu/mouse	1 ×	i.p.	Cisplatin	2.5 mg/kg	1 ×	i.v.	CT 3 days after IT	Inhibition	NT	$CD8^+$ CTL response	Apoptosis, enhancement of Ag-specific $CD8^+$ response	
	Vaccinia virus-encoding Sig/E7/L AMP-1	3×10^6 pfu/mouse	1 ×	i.p.	CY	50 mg/kg	1 ×	i.v.	CT 3 days after IT	Inhibition	NT	$CD8^+$ CTL response	Apoptosis, enhancement of Ag-specific $CD8^+$ CTL response	
	Vaccinia virus-encoding Sig/E7/L AMP-1	3×10^6 pfu/mouse	1 ×	i.p.	DOX	2.5 mg/kg	1 ×	i.v.	CT 3 days after IT	Inhibition	NT	$CD8^+$ CTL response	Apoptosis, enhancement of Ag-specific $CD8^+$ CTL response	

Tumor type	Vaccine IT				CT				Temporal relationship between IT and CT	Effect of combined therapy on		Possible mechanism of tumor growth inhibition		Ref.
	Composition	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration		Growth of established tumor	Survival after tumor challenge	IT	CT	
Murine cervical carcinoma (HPV-16 E7-expressing TC-1)	Vaccinia virus-encoding Sig/E7/L AMP-1	3×10^6 pfu/mouse	1 ×	i.p.	CH-DOX	6 mg/kg	1 ×	i.m.	CT 3 days after IT	Inhibition	Enhancement	$CD8^+$ CTL response	Enhancement of antitumor immune response via cross-presentation of apoptotic tumor body mediated by caspase activation	[61]
Murine colon carcinoma, fibrosarcom a, hepatoma	Recombin ant cFGFR	10 μg/mouse	4 ×	s.c.	Gemcitabine	10-20 mg/kg	4 ×	i.p.	IT 7 days before CT	Inhibition	Enhancement	Inhibition of tumor angiogenesis by anti-FGFR Ab induction	Apoptosis	[153,154]
Murine colon or lung carcinoma	Recombin ant endoglin	10 μg/mouse	4 ×	s.c.	Cisplatin	0.6 mg/kg	4 ×	i.p.	IT 7 days before CT	Inhibition	Enhancement	Inhibition of tumor angiogenesis by anti-endoglin Ab induction	Apoptosis	[141]
Murine colon carcinoma	Ad human HER-2/neu	2×10^8 pfu/mouse	1 ×	i.m.	Gemcitabine	60 mg/kg	2 ×	i.p.	IT 2 days after CT	Inhibition	NT	CD8+ CTL response	Apoptosis, elimination of myeloid-derived suppressor cells	[76]
	Anti-GITR Ab	500 μg/mouse	1 ×	i.p.	Gemcitabine	60 mg/kg	2 ×	i.p.	IT 4 days after CT	Inhibition	NT			
	α-galactosyl ceramide-loaded DC transduced with Ad human HER-2/neu	1×10^6 cells/mouse	1 ×	i.v.	Gemcitabine	60 mg/kg	1 ×	i.p.	IT 2 days after CT	Inhibition	NT			
Murine glioma	Survivin RNA-transfected DCs	1×10^6 cells/mouse	3 ×	s.c.	Temozolomide	2.5 mg/kg	5 ×	i.p.	IT 7 days after CT	NT	Enhancement	Survivin-specific CTL	Apoptosis, tumor Ag cross-priming	[72,109]
Mouse leukemia	Neuraminidasetreated leukemia cells + BCG	10^4 cells/mouse	1 ×	i.p.	BCNU	12 mg/kg	1 ×	i.p.	IT 36 hr after CT	NT	Enhancement	Ab-mediated CDC	Apoptosis by downregulation of Bcl-XL and Bcl-2	[19]

Tumor type	Vaccine IT				CT				Temporal relationship between IT and CT	Effect of combined therapy on		Possible mechanism of tumor growth inhibition		Ref.
	Composition	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration		Growth of established tumor	Survival after tumor challenge	IT	CT	
Murine lung carcinoma and hepatoma	Recombinant VEGFR	10 μg/mouse	4 ×	s.c.	Gemcit abine	20 mg/kg	4 ×	i.p.	IT 7 days before CT	Inhibition	Enhancement	Inhibition of tumor angiogenesis by induction of anti-VEGFR Ab	Apoptosis	[67]
Murine lymphoma cells transduced with HLA-A(*)02.01	Thymidylate synthase peptide + CFA	100 μg/mouse	4 ×	s.c.	5-FU	125 mg/mouse	4 ×	i.p.	CT 21 days after IT	Inhibition (prophylactic study)	NT	CTL	Apoptosis, enhancement of Ag-specific CTL and Ab-mediated CDC	[27]
Murine lymphoma cells transduced with HLA-A(*)02.01	Thymidylate synthase + CFA	100 μg/mouse	3 ×	s.c.	Gemcitabine	100 mg/mouse	3 ×	i.p.	CT 5 days after IT	NT	Enhancement	CTL	Apoptosis, enhancement of Ag-specific CTL and inhibition of Treg cells	[28]
					Oxaliplatin	50 mg/mouse	3 ×	i.p.						
					Leucovorin	100 mg/mouse	6 ×	i.p.	CT 1 day before IT	NT	No effect			
					5-FU	125 mg/mouse	6 ×	i.p.						
Rat osteosarcoma	Irradiated mouse B7-1 transduced tumor cells	10^6 cells/mouse	4 ×	i.p.	MTX	40 mg/kg	1 ×	i.p.	CT 4 weeks after IT	Inhibition	Enhancement	Enhancement of TIL and proliferative lymphocytes	Apoptosis	[65]

Abbreviations: 5-FC, 5-fluorocytosine; 5-FU, 5-fluorouracil; Ab, antibody; Ad, adenovirus; Ag, antigen; AML, acute myelogenous leukemia; BCG, Bacillus Calmette Guerin; BCNU, 1, 3-bis-(2-chloroethyl)-1-nitrosourea; CDC, complement-dependent cytotoxicity; CFA, complete Freund's adjuvant; cFGFR, chicken fibroblast growth factor receptor; CH-DOX, chitosan hydrogel containing doxorubicin; CT, chemotherapy; CTL, cytotoxic T lymphocyte; CY, cyclophosphamide; DC, dendritic cells; DOX, Doxorubicin; GITR, glucocorticoid-induced TNFR family-related receptor; HPV, human papilloma virus; i.m., intramuscularly; IT, immunotherapy; LAMP, lysosome-associated membrane protein; MTX, Methotrexate; NT, no tested; pfu, plaque forming units; s.c., subcutaneously; SINCP, Sindbis virus; TIL, tumor infiltrating lymphocytes; VEGFR, vascular endothelial growth factor receptor; VRP, Venezuelan equine encephalitis virus replicon particles.

Table 4

Clinical trials of combined active specific IT and CT

Tumor type	Vaccine IT				CT				Temporal relationship between IT & CT	No. of patients	Clinical outcome (No. of patients)	Possible mechanism of therapeutic effect		Ref.
	Designation (specificity)	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration				Vaccine	CT	
Colon cancer	TroVax-MVA (tumor Ag 5T4)	5×10^8 pfu	6 ×	i.m.	Oxaliplatin	350 mg/m^2	12 ×	i.v.	IT 4 days before CT	11	CR: 1 PR: 5 SD: 1 PD: 4	Induction of 5T4-specific IFN-γ and/or Ab responses	Apoptosis, enhancement of Ag-crosspresentation, activation of DCs	[63,64]
					5-FU	400-2400 mg/m^2	12 ×	i.v.						
					Folinic acid	350 mg/m^2	12 ×	i.v.						
Colon Cancer	Four mixed TAP with IFA	3mg	6 ×	s.c.	TS-1	20-80 mg/m^2	28 ×	p.o.	IT and CT simultaneously	11	SD: 4 PD: 7	Enhancement of TAP-specific CTL and/or Ab responses	Apoptosis, enhancement of Ag-crosspresentation, inhibition of Treg cells	[131]
Gliobla stoma	Autologous DC loaded with peptide from tumor cells or autologous tumor lysate	$10\text{-}40 \times 10^6$	3 ×	s.c.	Temozolomide	150-200 mg/m^2	312 ×	i.v.	CT after IT	12/12/1 2[a]	1/1/5[a] 2-yr DFS	Induction of tumorreactive CTL	Apoptosis	[148]
					BCNU	150-200	42 ×	i.v.						
Pancreatic cancer	Four mixed TAP with IFA	1-6 mg	8-63 ×	s.c.	Gemcitabine	1000 mg/m^2	6-48 ×	i.v.	IT and CT simultaneously	13	PR: 2 SD: 7 PD: 4	Enhancement of TAP-specific CTL and/or Ab responses	Apoptosis, enhancement of cellular responses	[150]
Prostate cancer	Four mixed TAP	4-12 mg	> 6×	s.c.	Estramustine phosphate	140 mg	1080 ×	p.o.	IT and CT simultaneously	3/13[b]	PR: 1; PD: 2/PR: 6; PD: 7[b]	Enhancement of TAP-specific IFN-γ and/or Ab responses	Apoptosis	[103]
Prostate cancer	rV-PSA	3.51×10^8pfu	1 ×	s.c.	DOX	30 mg/m^2	4 ×	i.v.	CT 1 day after IT	14/14[b]	1.8/3.2 mo PMT[b]	Induction of PSA-specific IFN-γ	Apoptosis	[6]
	rV-B7.1	1.17×10^8pfu	1 ×	s.c.										
	rF-PSA	1.5×10^9pfu	1 ×	s.c.								responses		

Tumor type	Vaccine IT				CT				Temporal relationship between IT & CT	No. of patients	Clinical outcome (No. of patients)	Possible mechanism of therapeutic effect		Ref.
	Designation (specificity)	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration				Vaccine	CT	
Small cell lung cancer	P53-transfected DCs	1-5 × 10^6	3 ×	i.d.	Carboplatin/VP-16	100-200 mg/m^2	9 ×	i.v.	IT after CT	21	CR: 3 PR: 10 SD: 4 PD: 4	Development of p53-specific IFN-γ responses	Downregulation of tumorproduced immunosuppressive factors	[4]
					Cisplatin/VP-16	30-100 mg/m^2	9 ×	i.v.						
					Cisplatin/C PT-11	30-125 mg/m^2	9 ×	i.v.						

Abbreviations: Ab, antibody; AML, acute myelogenous leukemia; BCG, Bacillus Calmette Guerin; BCNU, 1, 3-bis-(2-chloroethyl)-1-nitrosourea; CPT-11, irinotecan; CPT-11, irinotecan; CR, complete response; CT, chemotherapy; CY, cyclophosphamide; DC: dendritic cells; DFS, disease free survival; i.d. intradermally; IFA, incomplete Freund's adjuvant; IT, immunotherapy; MR, mixed response; MTX, Methotrexate; MVA: modified vaccinia Ankara; NR, no response; NT, no tested; OR, objective (>50%) regression; PD, progressive disease; p.o., per os; PMT: progression median time; PR, partial response; PSA, prostate-specific antigen; rF, recombinant fowlpox virus; rV, recombinant vaccinia virus; s.c., subcutaneously; SD, stable disease; TAP, tumor associated peptides; TAX, paclitaxel; TS-1,5-FU derivative; VP-16, etoposide;.

[a] CT/IT/CT+IT

[b] IT/IT+CT

Table 5

Pre-clinical and clinical studiies of combined adoptive lymphocyte or active specific IT and CT

Tumor type	Adoptive and active immunotherapy				CT				Temporal relationship between IT & CT	No. of patients or mice	Clinical outcome (No. of patients or mice)	Possible mechanism of therapy		Ref.
	Designation (specificity)	Dose	Frequency of application	Route of administration	Designation	Dose	Frequency of application	Route of administration				IT	CT	
Murine fibrosarcoma	Transferred Ag-specific T cells	5×10^6	1 ×	i.v.	Gemcitabine	200 ng/g	1 ×	i.p.	IT 2 days after CT	8	Rejection of tumor: 7	Tumor Ag-specific CTL	Apoptosis	[152]
Mela noma	Autologous antitumor lymphocytes	$2.3\text{-}13.7 \times 10^{10}$	1 ×	i.v.	CY	60 mg/kg	2 ×	i.v.	IT 1 day after CT	13	PR: 6 NR-mixed: 4 NR: 3	Tumor- Ag specific CTL	Depletion of Treg cells; altered homeostasis	[42,43,127]
					Fludarabine	25 mg/m^2	5 ×	i.v.						
	+ IL-2	720,000 IU/kg	15 ×	i.v.										
Melanoma	Autologous antitumor lymphocytes	$1.0\text{-}16.0 \times 10^{10}$	2 ×	i.v.	CY	30-60 mg/kg	2 ×	i.v.	IT 1 day after CT	35	CR: 3 PR: 15 NR-mixed: 8 NR: 9	Tumor Agspecific CTL	Depletion of Treg cells; altered homeostasis	[44]
					Fludarabine	25 mg/m^2	5 ×	i.v.						
	+ IL-2	720,000 IU/kg	15 ×	i.v.										
Melanoma	Melan-A peptide	100 μg	6 ×	s.c.	Busulfan	2 mg/kg	2 ×	p.o.	IT 3 or 5 days after CT	6	PR: 1 PD: 5	Tumor Ag-specific CTL	Depletion of Treg cells; altered homeostasis	[5]
					Fludarabine	30 mg/m^2	3 ×	i.v.						
	+ CpG	500 μg												
	+ IFA	300 μg												
	Melan-A specific $CD8^+$T cells	1×10^9	1 ×	i.v.										

Abbreviations: CR, complete response; CT, chemotherapy; CY, cyclophosphamide; IFA, incomplete Freund's adjuvant; i.p., intraperitoneally; IT, immunotherapy; i.v., intravenously; NR, no response; NR-mixed, mixed/no response; PD, progressive disease; p.o., per os; PR, partial response; s.c., subcutaneously.